Bioactive Technologies for Bone Replacement

Article preview from Medtech Insight - April, 2010

The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.

Article preview from Medtech Insight - April, 2010

Bioactive Technologies for Bone Replacement

Once considered the Holy Grail in bone replacement materials, Medtronic Inc.'s Spinal and Biologics Division's INFUSE Bone Graft, the first bone growth factor approved for use in the US, raised the bar in terms of clinical efficacy and has dominated the market for bone replacement materials since its approval in 2002. This recombinant bone morphogenetic protein (rhBMP)-2 has the ability to induce bone growth acroßs a repair site resulting in predictable healing and was PMA approved for use in conjunction with Medtronic's LT-CAGE for treating degenerative disc disease of the lumbar spine. Delivered on a bovine collagen sponge placed within an interbody fusion cage, INFUSE achieved rapid adoption after its release, primarily because it obviated the need to harvest an iliac crest bone graft from a secondary operative site, which is the major source of postoperative pain following spinal fusion. In 2004, INFUSE received a second PMA approval for repair of open long-bone fractures of the tibia. The company has completed an additional Investigational Device Exemption (IDE) study for posterolateral fusions and has another one for cervical fusion underway.

Today, INFUSE remains the only BMP that is PMA approved in the US. Its sole competitor, Stryker Corp.'s OP-1 (rhBMP-7), is approved under a Humanitarian Device Exemption (HDE) with separate HDEs for revision posterolateral spinal fusion and recalcitrant long-bone nonunions where autograft is not feasible and alternative treatments have failed. An HDE restricts usage to 4,000 patients a year. The product failed to receive a US Food & Drug Administration (FDA) advisory panel PMA approval recommendation last year for use in posterolateral lumbar spine fusion procedures, with the panel citing concerns about potential immunologic effects and problems with the company's clinical study design. Stryker reported about $50 million in sales of OP-1 in 2009.

BMPs under Attack

Medronic's INFUSE, on the other hand, generated approximately $776 million in sales in 2009, an increase of only 1% over the prior year. This slowdown in growth is largely attributed to a series of adverse events that have significantly hampered the product's use, including a public health notice from the FDA regarding off-label use in the cervical spine, a previously disclosed government investigation, negative newspaper reports, and a whistleblower lawsuit filed against a number of spine surgeons and distributors of INFUSE.

-Sharon O'Reilly  

Purchase this article online  as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satis faction Guaranteed. Subscribe to Medtech Insight.

Elsevier Business Intelligence announces the publication of a new Special Report "Bigger, Tougher,Faster"- Preparing for the New FDA. When the inspector comes calling ... will you be ready?
This 16-page report originally published in "The Silver Sheet". Learn more... 

Limited-time offer: Single-incision laparoscopy or natural orifice surgery: Which will win the day, or is there room for both? Are You Ready For The New Scarless Surgery Revolution? Download you FREE report now

About Medtech Insight

Medtech Insight newsletter provides insights into the technology and market developments (devices, instrumentation, biomaterials, gene therapy, tissue engineering, etc.) impacting a wide range of surgical and non-surgical clinical practices.